Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma

Over the last seven years, seven targeted agents have been approved in the treatment of advanced or metastatic renal cell cancer, changing the therapeutic approach and prognosis of the disease dramatically. The latest agent with demonstrated efficacy is axitinib (Inlyta®). This new generation of tyr...

Full description

Bibliographic Details
Main Authors:	Gross-Goupil, Marine, François, Louis, Quivy, Amandine, Ravaud, Alain
Format:	Online
Language:	English
Published:	Libertas Academica 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825605/

Similar Items

Optimal management of renal cell carcinoma in the elderly: a review
by: Quivy, Amandine, et al.
Published: (2013)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
by: Gross-Goupil, Marine, et al.
Published: (2012)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
by: Gunnarsson, Orvar, et al.
Published: (2015)

Axitinib in Metastatic Renal Cell Carcinoma
by: Mittal, Kriti, et al.
Published: (2012)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
by: Ansari, Jawaher, et al.
Published: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
by: Verzoni, Elena, et al.
Published: (2014)

Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
by: Koie, Takuya, et al.
Published: (2013)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
by: Escudier, Bernard, et al.
Published: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
by: Tyler, Timothy
Published: (2012)

Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Wang, Hai, et al.
Published: (2016)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
by: Chittoria, Namita, et al.
Published: (2016)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
by: Narayan, Vivek, et al.
Published: (2016)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
by: Grünwald, Viktor, et al.
Published: (2012)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
by: Escudier, B, et al.
Published: (2014)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
by: Atkins, Michael B, et al.
Published: (2015)

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
by: Koie, Takuya, et al.
Published: (2015)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
by: Alison C. Johnson, et al.
Published: (2017-05-01)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
by: Ueda, Takeshi, et al.
Published: (2013)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
by: Eto, Masatoshi, et al.
Published: (2014)

Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response
by: Diego Teyssonneau, et al.
Published: (2017-05-01)

Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
by: Shahani, Rohan, et al.
Published: (2010)

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
by: Ioka, Tatsuya, et al.
Published: (2015)

Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication
by: Socola, Francisco, et al.
Published: (2012)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
by: Cella, D, et al.
Published: (2013)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
by: Rini, Brian I., et al.
Published: (2014)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
by: Pithavala, Yazdi K., et al.
Published: (2010)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
by: Tortorici, Michael A., et al.
Published: (2010)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
by: Kerr, Lauren T., et al.
Published: (2016)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
by: Hillman, Gilda G., et al.
Published: (2014)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
by: Fujiwara, Yutaka, et al.
Published: (2011)

AB186. The efficacy and safety of sorafenib in Chinese patients with metastatic renal cell carcinoma and prognostic factors related to its efficacy
by: Yu, Xiaoteng, et al.
Published: (2015)

Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report
by: Yuki, Hideo, et al.
Published: (2014)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
by: Qin, Shukui, et al.
Published: (2015)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
by: Karakiewicz, Pierre I, et al.
Published: (2016)

Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells
by: Morelli, Maria Beatrice, et al.
Published: (2015)

Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
by: D'Aniello, Carmine, et al.
Published: (2016)

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
by: Suttle, A B, et al.
Published: (2014)

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
by: Suttle, A B, et al.
Published: (2014)

A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting
by: Fishman, Mayer N., et al.
Published: (2015)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
by: Martin, L P, et al.
Published: (2012)